|
Market Cap (4-Jul) $146,035,872 (477th) |
Close (30-Jun) $0.99 |
Volume (30-Jun) 1,077,429 |
Shortsold (19-Jun) 1,473,254 (0.38%) (338th) |
|
52w High $0.66 |
52w Low $0.165 |
P/E - |
EPS -0.05 |
PAR released this announcement to the ASX on 9 November 2022, 9:14. The announcement is not marked as price sensitive, and is 16 page(s) in length and 5.67MB in size.
You can view all announcements from PAR and see how they appear on a price chart on the announcements page.
At the date of this announcement, PAR was 0.896% short sold according to ASIC data. It was ranked the 250th most shorted stock on the ASX. It remains ranked 338th as of the latest reported data (19 June 2025).
| Other Recent Announcements from PAR | |
|---|---|
| Notification of cessation of securities - PAR | 29 June 2023, 16:43 |
| Primary and Secondary endpoints met in MPS I Trial | 6 June 2023, 12:28 |
| iPPS shows 3-year equivalent durability in OA Canine Study | 1 June 2023, 8:21 |
| Bell Potter Virtual Healthcare Conference presentation | 9 November 2022, 9:14 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 31 October 2022, 7:57 |
| Notice of Annual General Meeting/Proxy Form | 28 October 2022, 13:06 |
| Paradigm Doses First UK Participant in Phase 3 Trial | 26 October 2022, 9:35 |
You must be logged in to post a reply.
Paradigm Biopharmaceuticals 